Global Mice Model Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|小鼠模型的全球市場:2021年∼2028年 Global Mice Model Market - 2021-2028|
|出版日期: 2021年06月01日||內容資訊: 英文 180 Pages||
The global mice model market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
A mouse model is a laboratory mouse used to examine some aspect of human disease. Many different model organisms are used in this respect, but mice are particularly useful because they share mammalian traits with humans and suffer from many diseases.
The major factors driving the growth of this market are the growing demand for consumption of personalized medicine in developing and developed countries has fueled the demand for mice models.
The growing in the advancements in gene editing tools will drive the market growth
A rise in the improvements in gene editing tools will drive the mice model market growth. CRISPR-associated protein (Cas9) technology has transformed genome editing. Several novel utilization of CRISPR/Cas9 in a wide range of disorders have demonstrated its appearance and have been used in-vivo mice models significantly. For instance, the utilization of viral-mediated delivery of the CRISPR method to somatic cells of adult mice has resulted in Eml4-Alk-driven, the lung cancer mouse model creation, to study the disease features.
In addition, transgenic mice have been designed by incorporating Cas9 into mouse zygotes to understand the pathophysiology of cardiovascular disorders. CRISPR-Cas9 System has also implied in the generation of Kcnj13 mutant mice to examine ophthalmic disorders. The technology has further supported researchers in creating different types of immunodeficient models of mice.
For instance, in March 2019, the National Institute of Allergy and Infectious Diseases announced funding for projects to conduct direct comparisons, comprehensive characterization and further humanized immune system (HIS) mouse models. The growing demand to estimate the consequences of drugs on humans, coupled with a growing focus on studying human-specific infections, treatments, and immune responses, promotes the development and use of humanized mice models.
The growing demand for personalized medicine will drive the market growth
Personalized medicine is developing tailored medicines to provide individualized medication and care based on individual and genetic variations. These medicines are produced through the use of animal models. In this process, immunodeficient models are revamped with human tissues, and the disease expressed is recorded. It is followed by employing the model with drugs/gene therapeutics to find the most suitable medication, thus generating suitable or personalized medicines.
The development of therapeutics for key disorders such as cancer has attracted significant attention. Presently, cancer is a significant burden on the healthcare sector across the world. As per the data published by GLOBOCAN in 2020, it is expected that 19.3 million cases. In addition, growing geriatric population in the U.S. is the major factor for growing cancer incidence across the U.S. For instance, 87% of all cancers in the U.S. are diagnosed in people 50 years of age and older. Thus, mouse models can ensure the efficacy and efficiency of a particular drug molecule by conducting a massive number of clinical trials during the drug formulation process. Genetically engineered mouse (GEM) models are a mainstay for basic and translational cancer research.
Regulations and laws for the ethical use of animals in research will hamper the market growth in the forecast period
However, the implementation of laws and regulations for animal protection and welfare has enforced restrictive practices and bans on the use of animals for different purposes. In the last five years, many countries have banned the use of animals in the cosmetic industry. In 2018, Sri Lanka introduced a general animal welfare bill, and The Brazilian State of Minas Gerais banned cosmetic animal testing. In 2019, Australia banned the use of newly derived animal test data for cosmetics. Also, complying with mandatory regulations for the use of animal models is sometimes cumbersome and time-consuming and might hinder growth in the usage of animal models.
COVID-19 Impact Analysis
The COVID-19 pandemic has impacted the healthcare systems globally and also has a notable impact on the market. A large fraction of animal models is needed to verify the safety and effectiveness of new entities before leading human trials. As per the WHO, more than 20 vaccines are being developed ( some of them are devloped) beyond the globe for COVID-19. The market demand for COVID-19 mouse models is increasing, particularly for humanized ACE2 (hACE2) mice, which display human ACE2 in the airway and other epithelia and develop a lethal SARS-CoV infection. However, as mice model providers do not have readymade populations to meet growing demand, the current supply is limited.
Genetically engineered mice segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Genetically engineered mice help elucidate basic biological processes, study relationships between gene mutations and disease phenotypes, and modeling human disease. Mice can be engineered by inserting a targeting vector containing the gene of interest into a zygote or embryonic stem cells injected into a blastocyst.
Some genetically engineered and mutant mice strains have a mutation associated with a specific human disease. If the gene or mutation is orthologous in humans and causes the same disease in humans, the strain is designated as a model of the human disease. Manifestation of the genetic mutation (phenotypic expression) may differ between humans and mice. Investigators are strongly encouraged to research recommended mouse models to be sure they are appropriate for their research.
Oncology segment are expected to dominate the mice model market, by application, during the forecast period
The primary factor propelling the segment's growth is the growing burden of cancer and the increasing adoption of mice models in various oncology-related vaccine and drug development research. For instance, in August 2020, researchers of the American Chemical Society reported developing a novel type of immunotherapy for triple-negative breast cancer. The researchers estimated this treatment in mice models and resolved that it has dramatically elongated triple-negative breast cancer in the mice.
The Institute of Cancer Research, London, affirmed that mice could be genetically altered to study the genetic causes of cancer and generate tumor types that generally occur in humans. For this, they have been consolidating mice models in their pre-clinical tests for years. In 2017, 2018 and 2019, ICR listed the use of 26,320, 23,525, and 25,771 mice in pre-clinical oncology trials. These mouse models are presumed to revolutionize drug discovery analysis, improving and verifying various cancer treatments, including cancer immunotherapy. Thus, the technological advancements and funding by the major companies to include mice models in various phases of cancer therapy and diagnostic examinations. These factors will drive the segment growth in the forecast period.
North America region holds the largest market share in the global mice model market
North American region dominates the mice model market estimated for the largest market share in 2020. The strength of key players in the mice model market is the highest in the North American region. In addition, the increasing number of investments by the government for the advancement of innovations in mice models. For instance, NIDA has awarded a professor at The Jackson Laboratory of an exploratory grant of USD 212,500 to recognize genetic pathways implicated in addiction behaviors utilizing genome editing in mice models. Under the grant, the researchers will create five new mice models with variety in Cyfip2 using CRISPR/Cas9 gene-editing technology.
Additionally, market players are also concentrating on market improvement strategies to improve their market share in the region. For instance, in April 2019, Envigo and LabCorp announced that LabCorp's Covance Drug Development section would acquire Envigo's nonclinical research services business. Envigo's Research Models Services business will be taken the Covance Research Products business. These factors will drive the growth of the market in the region.
The mice model market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Charles River Laboratories, genOway, Aragen Bioscience, GenOway, Taconic, Oragenics Inc, Innovive, Jackson Laboratory, FENGSHI Group, Cyagen. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the mice model market globally.
Mice Model Market Key Companies to Watch
Overview: The Jackson Laboratory operates as a nonprofit organization focusing on mammalian genetics research to advance human health. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its research in cancer, immunology, and diabetes, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe.
Product Portfolio: The Company offers in vivo pharmacology, oncology services, immunology services, mice & services among others.
Key Development: In 2020, the Jackson Laboratory started the production of ACE2 mice to support the research on COVID-19.
The global mice model market report would provide an access to an approx. 61 market data table, 57 figures and 200 pages.
Global Mice Model Market - By Type
Global Mice Model Market - By Service
Global Mice Model Market - By Technology
Global Mice Model Market - By Application
Global Mice Model Market - By End User
Global Mice Model Market - By Region
LIST NOT EXHAUSTIVE